This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.An open-label, single-arm, phase II study according to Fleming's one-stage design. Ovarian cancer patients having achieved a clinical complete response to chemotherapy with a standard platinum and taxane regimen will receive four intraperitoneal infusions of catumaxomab through an in-dwelling port or catheter. All patients will be followed for safety and tolerability of catumaxomab therapy for a period of three months after the last infusion. Thereafter patients will switch to a 24 month post-study period in order to obtain long-term efficacy data.
Showing the most recent 10 out of 589 publications